| Title |
Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non–Small Cell Lung Cancer Growth and Metastasis
|
|---|---|
| Published in |
Cancer Prevention Research, January 2011
|
| DOI | 10.1158/1940-6207.capr-10-0181 |
| Pubmed ID | |
| Authors |
Anju Preet, Zahida Qamri, Mohd W Nasser, Anil Prasad, Konstantin Shilo, Xianghong Zou, Jerome E. Groopman, Ramesh K. Ganju |
| Abstract |
Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide; however, only limited therapeutic treatments are available. Hence, we investigated the role of cannabinoid receptors, CB1 and CB2, as novel therapeutic targets against NSCLC. We observed expression of CB1 (24%) and CB2 (55%) in NSCLC patients. Furthermore, we have shown that the treatment of NSCLC cell lines (A549 and SW-1573) with CB1/CB2- and CB2-specific agonists Win55,212-2 and JWH-015, respectively, significantly attenuated random as well as growth factor-directed in vitro chemotaxis and chemoinvasion in these cells. We also observed significant reduction in focal adhesion complex, which plays an important role in migration, upon treatment with both JWH-015 and Win55,212-2. In addition, pretreatment with CB1/CB2 selective antagonists, AM251 and AM630, prior to JWH-015 and Win55,212-2 treatments, attenuated the agonist-mediated inhibition of in vitro chemotaxis and chemoinvasion. In addition, both CB1 and CB2 agonists Win55,212-2 and JWH-133, respectively, significantly inhibited in vivo tumor growth and lung metastasis (∼50%). These effects were receptor mediated, as pretreatment with CB1/CB2 antagonists abrogated CB1/CB2 agonist-mediated effects on tumor growth and metastasis. Reduced proliferation and vascularization, along with increased apoptosis, were observed in tumors obtained from animals treated with JWH-133 and Win55,212-2. Upon further elucidation into the molecular mechanism, we observed that both CB1 and CB2 agonists inhibited phosphorylation of AKT, a key signaling molecule controlling cell survival, migration, and apoptosis, and reduced matrix metalloproteinase 9 expression and activity. These results suggest that CB1 and CB2 could be used as novel therapeutic targets against NSCLC. |
X Demographics
The data shown below were collected from the profiles of 86 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 18 | 21% |
| Indonesia | 4 | 5% |
| Japan | 4 | 5% |
| United Kingdom | 2 | 2% |
| Canada | 2 | 2% |
| China | 1 | 1% |
| India | 1 | 1% |
| North Macedonia | 1 | 1% |
| Austria | 1 | 1% |
| Other | 5 | 6% |
| Unknown | 47 | 55% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 80 | 93% |
| Practitioners (doctors, other healthcare professionals) | 4 | 5% |
| Scientists | 1 | 1% |
| Science communicators (journalists, bloggers, editors) | 1 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 185 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 3% |
| Hong Kong | 1 | <1% |
| France | 1 | <1% |
| Unknown | 178 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 31 | 17% |
| Student > Master | 28 | 15% |
| Student > Ph. D. Student | 27 | 15% |
| Student > Bachelor | 19 | 10% |
| Other | 13 | 7% |
| Other | 28 | 15% |
| Unknown | 39 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 33 | 18% |
| Biochemistry, Genetics and Molecular Biology | 32 | 17% |
| Medicine and Dentistry | 30 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 8% |
| Immunology and Microbiology | 5 | 3% |
| Other | 28 | 15% |
| Unknown | 43 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 267. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 October 2023.
All research outputs
#138,493
of 25,770,491 outputs
Outputs from Cancer Prevention Research
#20
of 1,461 outputs
Outputs of similar age
#518
of 192,700 outputs
Outputs of similar age from Cancer Prevention Research
#1
of 20 outputs
Altmetric has tracked 25,770,491 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,461 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.7. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 192,700 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.